We report the case of a patient with schizophrenia, who experienced agranulocytosis
during clozapine treatment, followed by bronchopulmonal infection and Guillain-Barré
syndrome. The case was recorded within the German surveillance project ”drug safety
in psychiatry” (AMSP) [2].
References
- 1
Buchwald B, Ahangari R, Weishaupt A, Toyka K V.
Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome.
Ann Neurol.
2002;
51
667-669
- 2
Grohmann R, Engel R R, Ruther E, Hippius H.
The AMSP drug safety program: methods and global results.
Pharmacopsychiatry.
2004;
37 (Suppl 1)
4-11
- 3
Hinze-Selch D, Becker E W, Stein G M, Berg P A, Mullington J, Holsboer F, Pollmächer T.
Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated
schizophrenic patients.
Neuropsychopharmacol.
1998;
19
114-122
- 4
Hinze-Selch D, Deuschle M, Weber B, Heuser I, Pollmächter T.
Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy
on blood cell counts, plasma levels of cytokines and body weight.
Psychopharmacology.
2000;
149
163-169
- 5
Löffler S, Fehsel K, Henning U, Fischer J, Agelink M, Kolb-Bachofen V, Klimke A.
Increased apoptosis of neutrophils in a case of clozapine-induced agranulocytosis
- a case report.
Pharmacopsychiatry.
2003;
36
37-41
- 6
Toyka K V.
Eighty three years of Guillain-Barre syndrome: clinical and immunopathologic aspects,
current and future treatments.
Rev Neurol (Paris).
1999;
155
849-56
- 7
Yuki N.
Infectious origins of, and molecular mimicry in, Guillain-Barre and Fisher syndromes.
Lancet Infect Dis.
2001;
1
29-37
Joachim Cordes, MD
Department of Psychiatry and Psychotherapy
Heinrich-Heine University
Bergische Landstr. 2
40629 Düsseldorf
Germany
Telefon: +49 211 922 3402
Fax: +49 211 922 3615
eMail: joachim.cordes@lvr.de
